title: Abdominal tuberculosis in children: review of 26 cases.
abstract: The protean clinical manifestations and varied complications of abdominal tuberculosis continue to challenge the diagnostic acumen and therapeutic skills of all physicians. Although abdominal tuberculosis in children has not been common in the United States over the past 2 decades, the authors found 26 case reports for the period 1980-1993. Three clinical patterns were evident: intestinal (13) peritoneal (9), and asymptomatic with incidental calcifications apparent on abdominal radiographs (4). The diagnosis was suspected for only 23% of these cases, which emphasizes the nonspecific symptomatology caused by this extrapulmonary manifestation and the need for a high index of suspicion to make a prompt diagnosis. In this study, 24 of the 26 (91%) were of Hispanic origin; the other two were indo-Chinese, another high-risk group. Most patients (88%) had a positive PPD skin test result. Mycobacteria were isolated from 15 of 21 (71.4%) cultures, with M bovis in 80% and M tuberculosis in 20%. Antituberculous chemotherapy is the mainstay of treatment; surgery is reserved for tissue diagnosis in cases of peritoneal tuberculosis and for the management of complications of intestinal tuberculosis. The response to chemotherapy usually is excellent, and long-term sequelae are uncommon. It appears that steroids do not decrease the incidence or degree of fibrosis in intestinal tuberculosis.
authors.affiliation: Department of Pediatric Surgery, Children's Hospital & Health Center, San Diego, CA, USA.
authors.forename: R S
authors.initials: RS
authors.lastname: Veeragandham
authors.forename: F P
authors.initials: FP
authors.lastname: Lynch
authors.forename: T G
authors.initials: TG
authors.lastname: Canty
authors.forename: D L
authors.initials: DL
authors.lastname: Collins
authors.forename: W M
authors.initials: WM
authors.lastname: Danker
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents / Q000627:therapeutic use; D002140:California / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D014395:Peritonitis, Tuberculous / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy; D011718:Pyrazinamide / Q000627:therapeutic use; D012189:Retrospective Studies; D012293:Rifampin / Q000627:therapeutic use; D014385:Tuberculosis, Gastrointestinal / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin